Rituximab as Induction Therapy After Renal Transplantation: A Randomized, Double‐Blind, Placebo‐Controlled Study of Efficacy and Safety

We evaluated the efficacy and safety of rituximab as induction therapy in renal transplant patients. In a double‐blind, placebo‐controlled study, 280 adult renal transplant patients were randomized between a single dose of rituximab (375 mg/m2) or placebo during transplant surgery. Patients were stratified according to panel‐reactive antibody (PRA) value and rank number of transplantation. Maintenance immunosuppression consisted of tacrolimus, mycophenolate mofetil and steroids. The primary endpoint was the incidence of biopsy proven acute rejection (BPAR) within 6 months after transplantation. The incidence of BPAR was comparable between rituximab‐treated (23/138, 16.7%) and placebo‐treated patients (30/142, 21.2%, p = 0.25). Immunologically high‐risk patients (PRA >6% or re‐transplant) not receiving rituximab had a significantly higher incidence of rejection (13/34, 38.2%) compared to other treatment groups (rituximab‐treated immunologically high‐risk patients, and rituximab‐ or placebo‐treated immunologically low‐risk (PRA ≤ 6% or first transplant) patients (17.9%, 16.4% and 15.7%, p = 0.004). Neutropenia (<1.5 × 109/L) occurred more frequently in rituximab‐treated patients (24.3% vs. 2.2%, p < 0.001). After 24 months, the cumulative incidence of infections and malignancies was comparable. A single dose of rituximab as induction therapy did not reduce the overall incidence of BPAR, but might be beneficial in immunologically high‐risk patients. Treatment with rituximab was safe.

[1]  M. Sarwal,et al.  A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  G. Tydén,et al.  A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. , 2012, Transplantation.

[3]  A. Wernerson,et al.  Pharmacodynamics of Rituximab in Kidney Allotransplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  J. Wang,et al.  Analysis of Subcutaneous (SQ) Alemtuzumab Induction Therapy in Highly Sensitized Patients Desensitized With IVIG and Rituximab , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  L. Joosten,et al.  The anti-CD20 antibody rituximab reduces the Th17 cell response. , 2011, Arthritis and rheumatism.

[6]  C. Werning [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.

[7]  Patricia A. Lovelace,et al.  Phenotypic Evaluation of B-Cell Subsets After Rituximab for Treatment of Acute Renal Allograft Rejection in Pediatric Recipients , 2011, Transplantation.

[8]  A. Webster,et al.  Interleukin 2 receptor antagonists for kidney transplant recipients. , 2004, The Cochrane database of systematic reviews.

[9]  A. Sinha,et al.  Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[10]  J. Chapman,et al.  Chronic renal allograft dysfunction. , 2005, Journal of the American Society of Nephrology : JASN.

[11]  J. Carbone,et al.  Alterations of naïve and memory B‐cell subsets are associated with risk of rejection and infection in heart recipients , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[12]  W. Allebes,et al.  SPECIFICITY AND Ig CLASS OF PREFORMED ALLOANTIBODIES CAUSING A POSITIVE CROSSMATCH IN RENAL TRANSPLANTATION: THE IMPLICATIONS FOR GRAFT SURVIVAL , 1993, Transplantation.

[13]  H. Koenen,et al.  A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  P. Nickerson,et al.  Pre‐Transplant Assessment of Donor‐Reactive, HLA‐Specific Antibodies in Renal Transplantation: Contraindication vs. Risk , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  E. Kimby Tolerability and safety of rituximab (MabThera). , 2005, Cancer treatment reviews.

[16]  Kenneth G. C. Smith,et al.  B-cell-depleting induction therapy and acute cellular rejection. , 2009, The New England journal of medicine.

[17]  Tom Greene,et al.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. , 2007, Clinical chemistry.

[18]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Obstetrics and gynecology.

[19]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[20]  H. Genberg,et al.  A Randomized, Doubleblind, Placebo-Controlled, Study of Single-Dose Rituximab as Induction in Renal Transplantation , 2009, Transplantation.

[21]  H. Genberg,et al.  ABO Incompatible Kidney Transplantations Without Splenectomy, Using Antigen‐Specific Immunoadsorption and Rituximab , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  O. Bairey,et al.  Late-Onset Neutropenia After Rituximab Treatment: Case Series and Comprehensive Review of the Literature , 2010, Medicine.

[23]  M. Sarwal,et al.  Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. , 2003, The New England journal of medicine.

[24]  U. Berg,et al.  ABO-Incompatible Kidney Transplantation Using Antigen-Specific Immunoadsorption and Rituximab: A 3-Year Follow-up , 2008, Transplantation.

[25]  E. Neumann-Haefelin,et al.  Long-term outcome of ABO-incompatible living donor kidney transplantation based on antigen-specific desensitization. An observational comparative analysis. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  L. Hilbrands,et al.  More on B-cell-depleting induction therapy and acute cellular rejection. , 2009, The New England journal of medicine.

[27]  L. Boon,et al.  In Vitro Effects of Rituximab on the Proliferation, Activation and Differentiation of Human B Cells , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.

[29]  R. Montgomery,et al.  Rituximab Prevents an Anamnestic Response in Patients With Cryptic Sensitization to HLA , 2013, Transplantation.

[30]  H. Ishida,et al.  Chronic Antibody‐Mediated Rejection Is Reduced by Targeting B‐Cell Immunity During an Introductory Period , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Annals of Internal Medicine.

[32]  H. Meier‐Kriesche,et al.  Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. , 2002, Journal of the American Society of Nephrology : JASN.

[33]  M. Stegall,et al.  The Effect of Desensitization Protocols on Human Splenic B‐Cell Populations In Vivo , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  G. Einecked,et al.  Banff 07 Classification of Renal Allograft Pathology : Updates and Future Directions , 2008 .